Concepedia

Author

Victor Joo

University of Lausanne

Also Known As

Joo, Victor, V. Joo, Victor S. Joo, Victor Joo, Victor S. Joo

25

Publications

820

Citations

10

H-Index

32

Concepts

All Affiliations

University of LausanneSwiss Vaccine Research InstituteUniversity Hospital of LausanneFred Hutch Cancer CenterCommissariat à l'Énergie Atomique et aux Énergies Alternatives
VJ

About

Victor Joo is an author at University of Lausanne specializing in medicine, immunology, and autoimmunity.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

56

2

Immunology

2

2

45

3

Engineering

1

1

11

4

Biomedical Engineering

1

1

11

5

Cell Biology

1

1

32

Victor Joo

×

8

Publications

156

Citations

8

H-Index

YearCitations

A highly potent antibody effective against SARS-CoV-2 variants of concern

Craig Fenwick, Priscilla Turelli, Laurent Perez,

Cell Reports

2021

47

Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway

Craig Fenwick, Juan-Luis Loredo-Varela, Victor Joo,

The Journal of Experimental Medicine

2019

32

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study

P Petit, Douglas Daoudlarian, S. Latifyan,

Annals of Oncology

2024

21

CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses

Alessandra Noto, Victor Joo, Antonio Mancarella,

Viruses

2022

13

A Novel Self-Assembled Liposome-Based Polymeric Hydrogel for Cranio-Maxillofacial Applications: Preliminary Findings

Victor Joo, Thiruganesh Ramasamy, Ziyad S. Haidar

Polymers

2011

11

The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection

Alessandra Noto, Madeleine Suffiotti, Victor Joo,

Frontiers in Immunology

2022

11

Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy

Douglas Daoudlarian, Amandine Ségot, Sofiya Latifyan,

Annals of Oncology

2024

11

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Victor Joo, Karim Abdelhamid, Alessandra Noto,

Nature Communications

2024

10

Page 1